Novizan (688105.SH): A cumulative repurchase of 1.01% of the company's shares at a cost of 98.4017 million yuan

Glonghui, May 13, 丨 Novizan (688105.SH) announced that as of May 10, 2024, the company had repurchased a total of 4,0282 million shares through the Shanghai Stock Exchange system, accounting for 1.01% of the company's total share capital of 400,010,000 shares. The lowest price for the repurchase transaction was 22.63 yuan/share, the highest price was 28.65 yuan/share, and the cumulative payment amount was 98.4017 million yuan (excluding transaction fees).

Gelonghui FinanceMay 13 06:20 ET

A subsidiary of Novizan (688105.SH) and a subsidiary of Shanghai Pharmaceutical reached a cooperation on businesses such as Alzheimer's disease blood test products

Novi Zan (688105.SH) announced that Nanjing Novi Zan Medical Technology Co., Ltd., a wholly-owned subsidiary of the company (“Novi...

Zhitong FinanceMay 10 05:51 ET

Novizan (688105.SH) reported first-quarter results, net profit of RMB 5.216,400

Novizan (688105.SH) released its report for the first quarter of 2024. The company achieved operating income of 3 during the reporting period...

Zhitong FinanceApr 26 11:34 ET

Novizan (688105.SH): Net profit of 4.5 million yuan to 5.5 million yuan for the first quarter is expected to turn a year-on-year loss into a profit

On April 17, GLONGHUI (688105.SH) announced that the first quarter of 2024 achieved operating revenue of 30,000 million yuan to 315 million yuan. Compared with the same period of the previous year (statutory disclosure data), it will increase by -219 million yuan to 12.81 million yuan, an increase of -0.7% to 4% over the previous year. Net profit attributable to owners of the parent company was 4.5 million yuan to 5.5 million yuan in the first quarter of 2024. Compared with the same period last year (statutory disclosure data), it will increase 55.12 million yuan to 56.12 million yuan, an increase of 109% to 111% over the previous year, turning a loss into a profit. 20

Gelonghui FinanceApr 17 03:58 ET

Nanjing Vazyme Biotech Unit Gets Nod to Register Six Medical Devices; Shares Slump 14%

Nanjing Vazyme Biotech(SHA:688105) has secured registration certificates for six new medical devices developed by its unit, Nanjing Novozan Medical Technology, according to a Monday filing on the Shan

MT NewswiresApr 15 03:00 ET

Novizan (688105.SH) subsidiary develops AD series diagnostic reagent products to obtain medical device registration certificate

Zhitong Finance App News, Novizan (688105.SH) announced that a series of diagnostic reagent products developed by Nanjing Novizan Medical Technology Co., Ltd., a wholly-owned subsidiary of the company, recently obtained a “Medical Device Registration Certificate”, namely beta amyloid 1-40 (Aβ1-40) test kit (chemiluminescence method), beta amyloid 1-42 (Aβ1-42) test kit (chemiluminescence method), phosphorylated Tau217 protein (p-TAU217) test kit (chemiluminescence method, phosphorylated Tau181 protein (Tau181 protein) p- Tau181) test kit (chemical

Zhitong FinanceApr 14 03:54 ET